SCHEMBL1368290

SCHEMBL1368290

COC(=O)c1ccc(CCO)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.50
LMNA P02545 2/20 0.50
PPARG P37231 1/20 0.50
NCOA2 Q15596 1/20 0.50
NCOA1 Q15788 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
MRGPRX4 Q96LA9 1/20 0.49
HPGD P15428 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
ATM Q13315 1/20 0.49
PARP1 P09874 1/20 0.44
CYP4A11 Q02928 4/20 0.42
CYP4F2 P78329 3/20 0.42
TP53 P04637 1/20 0.42
ALDH1A1 P00352 3/20 0.41
PRNP P04156 1/20 0.41
RECQL P46063 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2162296 0.90 HPGD (0.52) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL2162982 0.88 HPGD (0.55) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL6981207 0.87 HPGD (0.57) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL5887893 0.86 HPGD (0.53) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL1401544 0.85 LMNA (0.53) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL2412998 0.84 HPGD (0.50) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL7613895 0.84 LMNA (0.49) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL7612745 0.84 LMNA (0.49) NPSR1LMNAPPARGNCOA2NCOA1
Hydrochloric Acid SCHEMBL2410455 0.83 HPGD (0.49) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL7211399 0.83 HPGD (0.54) NPSR1LMNAPPARGNCOA2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4558494-A1 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS ITALFARMACO S.p.A. (IT) 2025-05-28 EP disclosed
WO-2024017897-A1 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS ITALFARMACO S.P.A. (IT) 2024-01-25 WO disclosed
US-11667630-B2 Nitrogen-containing 6-membered cyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2023-06-06 US disclosed
US-11667630-B2 Nitrogen-containing 6-membered cyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2023-06-06 US disclosed
US-11667630-B2 Nitrogen-containing 6-membered cyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2023-06-06 US disclosed
CN-111511736-B Nitrogen-containing 6-membered ring compound 旭化成制药株式会社 2023-03-24 CN disclosed
EP-3733665-B1 2-OXO-1,3,4-THIADIAZINAN-3-YL MOIETY CONTAINING COMPOUNDS WITH EP4 RECEPTOR AGONIST ACTIVITY ASAHI KASEI PHARMA CORP (JP) 2022-09-28 EP disclosed
US-20210188837-A1 NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND ASAHI KASEI PHARMA CORPORATION (JP) 2021-06-24 US disclosed
US-20210188837-A1 NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND ASAHI KASEI PHARMA CORPORATION (JP) 2021-06-24 US disclosed
US-10988468-B2 Nitrogen-containing 6-membered cyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2021-04-27 US disclosed
US-6207670-B1 USE TO INHIBIT GROWTH AND PROLIFERATION OF CELLS OF HIGHER ORGANISMS AND MICROORGANISMS SUCH AS BACTERIA, YEAST AND FUNGI AGOURON PHARMACEUTICALS, INC. 2001-03-27 US disclosed
EP-0674516-B1 ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS AGOURON PHARMA (US) 2000-02-02 EP disclosed
US-5945427-A INHIBIT GROWTH AND PROLIFERATION OF CELLS OF HIGHER ORGANISMS AND MICRORGANISMS SUCH AS FUNGI, BACTERIA AND YEASTS; TREATMENT FOR TUMORS, INFLAMMATION, PSORIASIS; IMMUNOSUPPRESSIVE ACTIVITY AGOURON PHARMACEUTICALS, INC. (US) 1999-08-31 US disclosed
US-5739141-A Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds AGOURON PHARMACEUTICALS, INC. (US) 1998-04-14 US disclosed
US-5726312-A Methods for preparing antiproliferative 5-substituted pyrimidone compounds AGOURON PHARMACEUTICALS, INC. (US) 1998-03-10 US disclosed
EP-0674516-A4 1995-10-25 EP disclosed
EP-0674516-A1 ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS AGOURON PHARMACEUTICALS, INC. (US) 1995-10-04 EP disclosed
WO-1994013295-A1 ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS AGOURON PHARMACEUTICALS, INC. (US) 1994-06-23 WO disclosed
EP-0415510-A2 L-glutamic acid derivatives THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1991-03-06 EP disclosed
US-4920125-A L-glutamic acid derivatives THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1990-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188837-A1 NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND PTGER4, EPB41, BMP4 NPSR1 127/4885LMNA 3902/4885PPARG 559/4885
US-10988468-B2 Nitrogen-containing 6-membered cyclic compound PTGER4, EPB41, BMP4 NPSR1 127/4885LMNA 3902/4885PPARG 559/4885
US-11667630-B2 Nitrogen-containing 6-membered cyclic compound PTGER4, EPB41, BMP4 NPSR1 127/4885LMNA 3902/4885PPARG 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.